338982-12-0 Usage
Uses
Used in Organic Synthesis:
3-(2-chlorophenyl)-5-isoxazolecarboxylic acid is used as a building block in organic synthesis, providing a foundation for the creation of more complex molecules with specific properties.
Used in Drug Development:
3-(2-CHLOROPHENYL)-5-ISOXAZOLECARBOXYLIC ACID is utilized in drug development as a key intermediate, contributing to the synthesis of pharmaceuticals with potential therapeutic applications.
Used in Research Chemicals:
3-(2-chlorophenyl)-5-isoxazolecarboxylic acid is used as a research chemical, facilitating the study of isoxazole-containing compounds and their potential pharmaceutical applications. Its presence in research helps to explore the compound's properties and its role in the development of new drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-(2-chlorophenyl)-5-isoxazolecarboxylic acid is of interest due to the isoxazole ring's potential biological activity. This makes it a valuable component in the design and synthesis of new drugs targeting various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 338982-12-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,8,9,8 and 2 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 338982-12:
(8*3)+(7*3)+(6*8)+(5*9)+(4*8)+(3*2)+(2*1)+(1*2)=180
180 % 10 = 0
So 338982-12-0 is a valid CAS Registry Number.
338982-12-0Relevant academic research and scientific papers
Novel Compounds
-
, (2017/07/06)
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
